Modern Imaging of Pituitary Adenomas

Waiel Bashari MSc MRCP(UK)\textsuperscript{1*}, Russell Senanayake MSc MRCP(UK)\textsuperscript{1*}, Antía Fernández-Pombo MD\textsuperscript{1,2*}, Daniel Gillett MSc\textsuperscript{3}, Olympia Koulouri MRCP(UK)\textsuperscript{1}, Andrew S Powlson MRCP(UK)\textsuperscript{1}, Tomasz Matys PhD FRCP\textsuperscript{4}, Daniel Scoffings FRCP\textsuperscript{4}, Heok Cheow FRCP\textsuperscript{3,4}, Iosif Mendichovszky PhD FRCP\textsuperscript{3,4}, Mark Gurnell PhD FRCP\textsuperscript{1}

Cambridge Endocrine Molecular Imaging Group, \textsuperscript{1}Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, and Departments of \textsuperscript{3}Nuclear Medicine and \textsuperscript{4}Radiology, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Hills Road, Cambridge, UK, CB2 0QQ; \textsuperscript{2}Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, Spain.

WB\textsuperscript{*}, RS\textsuperscript{*} and AF-P\textsuperscript{*} contributed equally to the manuscript.

\textbf{Abbreviated title:} Modern Pituitary Imaging

\textbf{Word count:} abstract 139; text 3510 (excluding references); tables 3; figures 9.

\textbf{Corresponding author:} Professor M Gurnell, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Box 289, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK; Tel +44-1223-348739; Fax +44-1223-330598; E-mail \texttt{mg299@medschl.cam.ac.uk}

\textbf{Funding:} This work was supported by the UK NIHR Cambridge Biomedical Research Centre (WB, OK, ASP, IM, MG)
Abstract

Decision-making in pituitary disease is critically dependent on high quality imaging of the sella and parasellar region. Magnetic resonance imaging (MRI) is the investigation of choice and, for the majority of patients, combined T1 and T2 weighted sequences provide the information required to allow surgery, radiotherapy (RT) and/or medical therapy to be planned and long-term outcomes to be monitored. However, in some cases standard clinical MR sequences are indeterminate and additional information is needed to help inform the choice of therapy for a pituitary adenoma (PA). This article reviews current recommendations for imaging of PA, examines the potential added value that alternative MR sequences and/or CT can offer, and considers how the use of functional/molecular imaging might allow definitive treatment to be recommended for a subset of patients who would otherwise be deemed unsuitable for (further) surgery and/or RT.

Key Words: pituitary, MRI, CT, PET, functional imaging, molecular imaging
Introduction

Although almost always benign, pituitary adenomas (PA) can be associated with significant morbidity and even increased mortality by virtue of hormone hypersecretion (e.g. acromegaly, Cushing syndrome), hypopituitarism, and local mass effects (e.g. visual loss due to chiasmal compression). Recent studies indicate a prevalence rate that is 3.5 to 5-times higher than previously suspected, with clinically-apparent tumours affecting between 1:1000 and 1:1500 of the general population(1). It is possible this still represents an underestimate bearing in mind up to 14.4% (in autopsy studies) and up to 22.5% (in radiologic studies) of the population have been reported to have a pituitary abnormality, but not all of these undergo formal endocrine assessment(2).

In recent years, the repertoire of medical therapies available for the management of pituitary tumours has increased significantly [e.g. the advent of GH receptor (GHR) antagonist or 2nd generation somatostatin receptor ligand (SRL) therapy for acromegaly](3). In addition, modern radiotherapy techniques (including stereotactic radiosurgery) allow for more precise targeting of a pituitary adenoma while sparing surrounding structures. However, for many patients pituitary surgery remains an important, often first, step in their management (either with curative intent or to reduce tumour bulk and facilitate more effective adjunctive treatment). Good quality imaging of the sella and parasellar regions is therefore critical to decision-making, even when surgery and/or radiotherapy are not recommended. For most patients, this means undergoing dedicated pituitary magnetic resonance (MR) imaging (MRI), which provides important information about the adenoma itself and key surrounding structures. In a small number of cases, pituitary computed tomography (CT) is required (most commonly when MRI is not possible/tolerated). However, while MRI and/or CT provide sufficient information for the management of the majority of cases, routine clinical sequences do not always reliably identify the site of de novo, persistent or recurrent adenoma, which in turn may reduce the opportunity for curative surgery and/or radiotherapy (RT).
Accordingly, several groups have explored the potential utility of using alternative MR sequences to inform the management of different pituitary tumour subtypes. In addition, we and others have examined the role(s) of functional imaging (e.g. using molecular PET tracers), in combination with MRI, to allow more accurate localisation of the site(s) of PA. This article provides an update on current approaches to imaging in pituitary adenomas, reviews possible indications for adopting specific MR (and/or CT) sequences and considers how advances in molecular PET imaging might be used to improve patient outcomes from targeted therapies such as (repeat) transsphenoidal surgery (TSS) or stereotactic radiosurgery (SRS).
Magnetic Resonance Imaging

MRI is the preferred cross-sectional imaging modality for identifying lesions within the pituitary gland and surrounding parasellar region, and provides a high detection accuracy (4–6). When requesting a pituitary MR scan, several factors should be taken into account (Table 1).

Insert Table 1 here

The normal anterior pituitary gland is isointense to grey matter on non-contrast T1 and T2 weighted standard Spin Echo (SE) sequences (Fig. 1a,b,e,f), while the posterior pituitary has intrinsic high T1 signal (Fig. 1b) but is hypointense on T2. Following contrast injection, the infundibulum and gland progressively enhance (Fig. 1c,d); however, contrast uptake by pituitary adenomas is typically slower, giving rise to delayed enhancement and washout characteristics, which can help to reveal an otherwise poorly visualised microadenoma (Fig. 2a). Gadolinium, a naturally-occurring lanthanide, is the most commonly employed contrast agent during pituitary imaging. It is particularly suited for use as an MRI contrast agent because it has seven unpaired electrons which confer strong paramagnetic properties. In its free form Gadolinium is toxic and it must therefore be chelated to a carrier ligand to allow clinical use. Gadolinium-based contrast agents (GBCAs) can be divided into four groups according to whether the carrier ligand is linear or macrocyclic and ionic or non-ionic. In recent years concern has been raised regarding the safety of GBCAs, and the pituitary community has been alerted to the potential for long-term central nervous system retention even in patients with normal renal function, which is particularly relevant given the need for many pituitary patients to continue with long-term imaging surveillance (7). Macrocyclic GBCAs exhibit greater chemical stability than their linear counterparts, and this has been linked to a lower risk of nephrogenic systemic fibrosis and reduced gadolinium tissue deposition; however, they appear to carry a higher risk of allergic reactions, albeit still
relatively rare. Therefore, while GBCAs continue to play an important role in imaging of the sella and parasellar region, it is important to consider when contrast might not be required [e.g. when T1 non-contrast and/or T2 sequences alone can provide sufficient information to inform management (see below)], thereby minimising exposure(8).

**Insert Figure 1 here**

Another important consideration when imaging the sella is the choice of magnetic field strength. 1.5T SE MRI is still commonly used in routine clinical practice and provides reasonable spatial resolution to permit 2.0 mm or 3.0 mm slice thickness. However, very small microadenomas (e.g. Cushing, thyrotropinoma) may escape detection, although this risk can be partially mitigated by careful selection of the T1 SE parameters(9). In recent years, higher field strength MRI systems (3T and more latterly 7T) have become available, providing higher signal to noise ratio with a reduction in acquisition time, and allowing 1.0 mm sections to be performed(10–12). Therefore, while 1.5T SE MRI is a reasonable option in the first instance, for those patients with suspected microadenomas but with equivocal or ‘negative’ 1.5T scans, referral for a 3T study should be considered(13). However, it remains to be seen whether using 7T MRI brings sufficient additional benefits to outweigh potential challenges such as the identification of a greater number of incidental pituitary abnormalities.

In routine clinical practice, most PA are readily visualised on T1 and T2 weighted MRI which provide important information about the size of the lesion [micro- (<1cm) versus macro-(≥1cm) adenoma] and the degree of parasellar involvement (Fig. 2). Several approaches have been proposed to define the extent of lateral extension and cavernous sinus invasion, with the most commonly used being the Knosp classification(14). As a general rule, the higher the grade, the greater the degree of cavernous sinus involvement, and the lower the probability of achieving full surgical remission. The inclusion of Grades 3A and 3B
differentiates between the different outcomes for adenomas invading the superior and the inferior cavernous sinus compartments (Fig. 2d)(15).

Insert Figure 2 here

Dynamic contrast-enhanced MRI (based on T1 weighted images obtained pre-and immediately following gadolinium injection) (Table 1) may be indicated when standard sequences have failed to identify a pituitary lesion but clinical features strongly suggest the presence of an adenoma, for example in suspected Cushing disease due to an ACTH-secreting microadenoma(5,16). However, gradient echo [e.g. spoiled gradient echo (SGE) / (fast) spoiled gradient recalled echo (FSPGR/SPGR)] has been reported to offer greater sensitivity for detecting corticotroph microadenomas with only occasional cases detected on dynamic but not gradient echo MRI(16). Strategies such as the administration of corticotrophin-releasing hormone immediately prior to scanning have not provided convincing evidence of an additional benefit(13).

Recently, there has been a resurgence of interest in the potential added value that T2 sequences can offer when assessing pituitary lesions – in particular, offering diagnostic insights that are not deducible from T1 sequences, and also potentially sparing the need for contrast enhanced imaging in some patients (thus reducing GBCA exposure – see above). Jean-François Bonneville has elegantly made the case for increased use (and reporting in the literature) of T2 MR findings in several pituitary disorders, and these are summarised in Table 2(8).

Insert Table 2 here

An array of alternative MR sequences, which are routinely employed in other clinical contexts, have also been tried in several pituitary disorders with mixed results (Table 3).
Although several have shown potential promise, for the most part findings need confirmation in larger cohorts before they can be recommended for routine clinical use.

*Insert Table 3 here*

**Computed tomography (CT)**

Modern computed tomography (CT) is a reasonable substitute where MRI is contraindicated (including in patients with non-MR compatible pacemakers/cardiac devices, vascular clips or metallic foreign bodies) or when the patient declines MRI (e.g. due to claustrophobia). Reasonable evaluation of pituitary macroadenomas is possible with dedicated pituitary CT (Fig. 3a), but it is generally less informative for the assessment/detection of small tumours, although advanced CT techniques (e.g. dynamic contrast-enhanced multisection CT) have been trialled and may even aid the detection of conventional MR imaging-occult pituitary microadenomas(17).

Even when MRI is possible, there are several situations in which CT can provide useful additional information regarding a sella-based or parasellar lesion. These include identification of bone destruction (e.g. by an invasive macroprolactinoma) (Fig. 3b) and confirmation of suspected intra/parasellar calcification [e.g. calcified PA (with thyrotropinoma being the classic example) or craniopharyngioma] (Fig. 3c). CT is also used in conjunction with MRI to facilitate radiotherapy planning and may reveal previously unsuspected tumour invasion of bony structures(18,19).

*Insert Figure 3 here*

**Functional Pituitary Imaging**
Despite recent advances in cross-sectional imaging, there remain several situations in which clinical decision-making is limited by indeterminate MRI and/or CT findings, including:

(i) small PA that cannot be readily visualised even using a combination of sequences (e.g. corticotroph adenomas may evade detection in 30-40% of patients with Cushing disease\(^{(20)}\); similarly, thyrotroph and lactotroph tumours are not always easily localised)

(ii) following primary intervention (surgery, radiotherapy or medical therapy) when post-treatment change may be difficult to distinguish from residual functioning tumour

(iii) in the presence of a confounding pituitary incidentaloma

Functional imaging represents an alternative and complementary approach to traditional anatomical imaging and has found widespread use in many endocrine disorders [e.g. technetium-99m-pertechnetate and technetium-99m-sestamibi scintigraphy in hyperthyroidism and hyperparathyroidism respectively; \(^{123}\)I-metaiodobenzylguanidine (\(^{123}\)I-MIBG) scintigraphy for detection of phaeochromocytoma/paraganglioma]. However, while scintigraphy remains a useful clinical technique, especially when combined with single photon emission computed tomography (SPECT) for image acquisition, its application in other fields of endocrinology has been limited by its modest sensitivity for detecting small lesions.

Positron emission tomography (PET) offers a solution to this problem and can be combined with CT (PET/CT) or MRI (PET/MR) to allow detection of even subcentimetre lesions. The development of PET ligands targeting different cellular processes (e.g. glucose or amino acid uptake, receptor or intracellular enzyme expression) has opened up new opportunities for the application of PET in endocrine disorders. The potential superiority of PET over conventional scintigraphy is exemplified by the comparison of \(^{111}\)Indium-pentetreotide scintigraphy (± SPECT) (‘octreoscan’) and \(^{68}\)Gallium-DOTATATE PET/CT for the
investigation of neuroendocrine tumours (NET), where the latter often detects lesions not seen on a conventional octreoscan(21).

To date, functional imaging has found limited use in the routine management of pituitary adenomas, although several groups have explored various modalities including somatostatin receptor scintigraphy (SRS) or PET, $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG)-PET and $^{11}$C-methionine($^{11}$C-Met)-PET.

**Somatostatin Receptor Scintigraphy and PET**

Somatostatin receptors (SSTRs) are expressed in normal human pituitary tissue and, to varying degrees, in different subtypes of pituitary adenoma. For example, somatostatin receptor subtype 2 (SSTR2) is detectable in most somatotroph adenomas, whereas SSTR5 expression is more variable(22). In contrast, corticotroph adenomas express higher levels of SSTR3 and SSTR5, but have also recently been confirmed to express SSTR2A(23). The use of Somatostatin Receptor Scintigraphy (e.g. $^{111}$Indium-pentetreotide) in the investigation and management of PA is therefore confounded by several factors: background uptake by normal pituitary tissue; dependence on SSTR subtype expression of the tumour; and limited spatial resolution and sensitivity of scintigraphy, even when combined with SPECT. $^{68}$Ga-DOTATATE PET has the potential to address the latter, but it has yet to find clear utility in the management of PA, although preliminary data suggests that combination with $^{18}$F-FDG PET may allow distinction of normal gland and adenoma in some cases of primary and recurrent disease(24,25).

**$^{18}$F-FDG PET**

The literature contains numerous case reports of incidentally-detected $^{18}$F-FDG uptake by pituitary adenoma(26–29). In contrast, in a large retrospective analysis of incidental pituitary uptake in >40,000 patients who had undergone whole body FDG PET/CT, the overall incidence was just 0.073%(30). Together these findings (demonstrable uptake by PA with a
negligible false positive rate) suggest a possible role for $^{18}$F-FDG PET in pituitary imaging. Indeed, the potential utility of $^{18}$F-FDG PET has been explored in various subtypes of PA (24,25), but has been most extensively studied in the context of corticotroph tumours, which often evade detection on MRI. However, findings have been largely disappointing. In a prospective study of ten consecutive patients with subsequently confirmed CD, high resolution $^{18}$F-FDG PET ($^{18}$F-FDG hrPET) was performed together with SE and SPGR MRI (31). $^{18}$F-FDG hrPET revealed increased tracer uptake in four patients, two of whom had no demonstrable lesion on SE MRI. However, SPGR proved more sensitive than $^{18}$F-FDG hrPET, identifying a pituitary adenoma in seven cases and, importantly, no adenomas were detected by $^{18}$F-FDG hrPET that were not visualised on SPGR MRI. A comparable detection rate (58%) was reported by Alzahrani and colleagues in their retrospective study of 12 patients who underwent conventional $^{18}$F-FDG PET/CT (32). Accordingly, $^{18}$F-FDG PET has yet to find a place in the routine management of PA.

$^{11}$C-methionine PET

Several groups have demonstrated the potential utility of $^{11}$C-methionine PET/CT (Met-PET/CT) in different pituitary tumour subtypes, both for the localisation of de novo tumours, especially microadenomas, and also for the identification of persistent or recurrent disease (18,33–36). However, a key limitation of Met-PET/CT is the relative lack of anatomical detail provided by CT when compared with MRI. This has led us and other workers to explore the possibility of fusing functional images derived from PET-CT with cross-sectional images obtained during volumetric MRI (e.g. FSPGR MRI) (35–38). In this way, the precise site(s) of $^{11}$C-methionine uptake can be delineated through coregistration of PET/CT and MRI images. With the advent of PET/MR this process will become even easier and more convenient, as has been demonstrated with other tracers (25).
However, several important considerations must be taken into account when developing a specialist pituitary imaging service using $^{11}$C-methionine PET.

**Patient selection and preparation**

Careful case selection is important. The majority of patients with PA do not require molecular imaging. However, the ability to correlate structure with function is potentially useful when either a small *de novo* functioning tumour (e.g. in Cushing disease, thyrotropinoma, prolactinoma or, less commonly, acromegaly), or residual/recurrent functioning PA (e.g. acromegaly) cannot be reliably identified on good quality MRI, and when definitive treatment (TSS or SRS) would otherwise be considered. As molecular imaging with $^{11}$C-methionine depends on the presence of functioning adenoma tissue, it is important to ensure adequate washout of agents that might otherwise suppress hormone production by the tumour [e.g. SSA or dopamine agonist (DA) therapy in acromegaly], and to confirm active disease prior to imaging. We recommend discontinuation of short-acting SSA therapy (i.e. octreotide) and DA at least one month prior to scanning. For depot SSA (e.g. Sandostatin LAR® or Lanreotide Autogel®) a longer washout period is required (typically 3 months). Patients should be instructed to fast for at least 4 hours before the scan. On the day, a further assessment of disease activity [paired random GH and IGF-1 in acromegaly; paired 9am adrenocorticotropic hormone (ACTH) and cortisol followed by late night salivary cortisol in Cushing syndrome; paired free thyroxine and TSH in thyrotropinoma; prolactin in prolactinoma], together with assessment of remaining pituitary function, should be undertaken.

**Tracer production**

Carbon-11 ($^{11}$C) has a half-life of just 20 minutes and is synthesised using a particle accelerator (Cyclotron). Following production, several quality control steps (identification, purity, stability, half-life confirmation, pH detection and substance sterility) must be completed.
before the tracer can be administered (39). The short half-life therefore limits its use to centres with an in-house cyclotron. Typically, between 100 and 400 MBq is administered intravenously.

**PET acquisition**

Uptake time is typically standardised (e.g. 20 min) following tracer injection. Acquisition of low dose CT images allows for attenuation correction (AC) of the PET dataset. A similar approach is required for hybrid PET/MR systems (40–43).

**PET/CT-MRI coregistration**

$^{11}$C-methionine PET/CT coregistration to independently acquired MRI (Met-PET-MRI$^{\text{CR}}$) can be performed using commercially available image fusion software. Amongst the most commonly used are automated (e.g. GE Xeleris®) and manual (e.g. MedCom Prosoma® and Slicer®) systems (44–46). Volumetric (1mm thickness) MRI facilitates coregistration.

$^{11}$C-methionine PET/CT-MRI findings in different PA subtypes

**Prolactinoma**

Lactotroph PA generally demonstrate avid $^{11}$C-methionine uptake (up to 9 times background brain uptake). In patients with hyperprolactinaemia for whom medical therapy with DA is not tolerated or advised, and in whom pituitary MRI is indeterminate, Met-PET-MRI$^{\text{CR}}$ can facilitate localisation of the tumour to guide selective TSS (Fig. 4). Similarly, in drug resistant macroprolactinomas the site(s) of residual disease can be readily localized to help the pituitary multidisciplinary team decide whether surgery or RT is appropriate (Bashari, Koulouri and Gurnell, unpublished data).

*Insert Figure 4 here*
**Acromegaly**

Similar to lactotroph tumours, somatotropinomas avidly take up $^{11}$C-methionine and Met-PET-MRI$^{CR}$ can help distinguish metabolically active residual/recurrent PA from scar tissue(36). As indicated above, certain types of medical therapy (e.g. SSA, DA) can diminish tracer uptake and appropriate washout should be completed before imaging is performed(36).

*Insert Figure 5 here*

**Cushing disease**

$^{11}$C-methionine uptake by corticotroph adenomas is typically less than is seen in other pituitary tumour subtypes. Possible reasons for this include the relatively low representation of corticotrophs amongst anterior pituitary cells (10-20%); their localization in the centre of the gland (leading to additional challenges due to tumoral tracer uptake merging with that of the normal gland); in addition, the periodic/cyclical nature of ACTH production in some corticotroph tumours may result in low uptake if the patient is scanned when the tumour is relatively quiescent (hence the need to confirm active disease at the time of imaging). Accordingly, success rates for localizing de novo or recurrent corticotroph tumours are of the order of ~70% (Fig. 6).

*Insert Figure 6 here*

**TSH-secreting PA (thyrotropinoma)**

The majority of thyrotroph tumours demonstrate avid uptake of $^{11}$C-methionine (Fig. 7). We have also shown that this uptake can be suppressed by SSA therapy, thus providing an 'endocrine switch' which can offer added reassurance when MR findings are unconvincing for the presence of an adenoma(37).
Clinically non-functioning pituitary adenoma / gonadotropinoma

Clinically non-functioning PAs (NFPA) and functioning gonadotropinomas also demonstrate significant $^{11}$C-methionine uptake which can therefore be used as a biomarker of residual/recurrent disease (Fig. 8).

Reassuringly, $^{11}$C-methionine uptake by cystic pituitary lesions within the sella is typically low/absent when compared with the normal background pituitary tissue or a PA (Fig. 9).
Summary

In the majority of cases when pituitary imaging is indicated, good quality T1 (± contrast enhancement) and T2 weighted sequences will provide sufficient information to allow effective clinical decision making. For those patients in whom MRI findings are inconclusive, consideration should be given to the use of other MR sequences, but these should only be requested following discussion with the pituitary multidisciplinary team (MDT). When MRI is not possible or tolerated, thin slice pituitary CT is a reasonable alternative, while in other situations it can augment the findings from MRI (e.g. when bony invasion/destruction is suspected). Although functional imaging with molecular PET tracers (e.g. $^{11}$C-methionine) is unlikely to find widespread usage, emerging evidence suggests that in a subgroup of patients it may play an important role in facilitating (further) definitive intervention (e.g. TSS or RT), thereby sparing patients and healthcare systems the need for long-term, often expensive, medical therapy. The establishment of a small number of centres with expertise in molecular pituitary imaging may sit comfortably with the recently proposed model for Pituitary Tumor Centres of Excellence (PTCOE)(47).

Practice Points

- All clinicians involved in the management of pituitary patients should have a good understanding of the MR sequences that are routinely used for pituitary imaging in their centre and when to consider alternative MR protocols.
- The decision to request gadolinium-enhanced MR sequences (e.g. T1 weighted with contrast) should include careful consideration of recent concerns raised regarding gadolinium deposition with GBCAs – if in doubt then discuss with the pituitary MDT and consider the use of alternative sequences (e.g. T2 weighted).
- Pituitary CT is indicated when MRI is not possible or tolerated, and when there is concern regarding bone invasion/destruction or intratumoral calcification.
- Functional imaging with the molecular tracer $^{11}$C-methionine (Met-PET-MRI$^{(CR)}$) can help
identify de novo or residual/recurrent PA in all tumour subtypes when MRI findings are inconclusive.

Research Agenda

- It remains unclear whether the advent of MR scanners with increased magnetic field strength (e.g. 7T) will bring added benefits that outweigh the potential disadvantages of identifying a greater proportion of confounding incidental pituitary lesions. Further studies are awaited.
- Although several MRI protocols that find routine use in other clinical settings (e.g. DWI, Elastography) have been applied to pituitary imaging with promising results, further studies are needed to determine whether these should be adopted in routine clinical practice.
- Functional imaging with the molecular tracer $^{11}$C-methionine (Met-PET-MRI$^{\text{CR}}$ or Met-PET/MRI) shows significant promise for producing a step change in the management of a subgroup of patients with PA. However, challenges remain when handling the raw datasets and collaborative studies drawing on the expertise of colleagues in the applied sciences (mathematics, physics) will likely be required to take image analysis to the next level.
Disclosures

None of the authors have anything to disclose.

Acknowledgements

This work was supported by the UK NIHR Cambridge Biomedical Research Centre and by the Evelyn Trust.

Author ORCID IDs

Waiel Bashari 0000-0002-2204-9169
Russell Senanayake 0000-0002-4141-1709
Antia Fernandez-Pombo 0000-0002-1268-7538
Olympia Koulori
Andrew Powlson
Daniel Scoffings
Iosif Mendichovszky 0000-0002-3777-2827
Heok Cheow
Mark Gurnell 0000-0001-5745-6832
References:


14.* Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with


33. Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine–positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent...


features with contrast-enhanced 3D FIESTA at 3T. Am J Neuroradiol. 2014;

Table 1. Points to consider when requesting a pituitary MRI protocol

<table>
<thead>
<tr>
<th>Key questions</th>
<th>Options / examples</th>
</tr>
</thead>
</table>
| Which sequences?                     | Spin Echo (SE) / Fast Spin Echo (FSE):  
- T1 weighted\(^1,2\)  
- T2 weighted  
- proton density (PD) weighted\(^2\)  
Gradient Echo (GE):  
- spoiled gradient echo (e.g. to permit thinner slices through the sella – see below)  
Other:  
- Diffusion weighted (DWI)  
- Perfusion weighted (PWI)  
- Inversion recovery (IR)  
- Fluid attenuation inversion recovery (FLAIR)  
- Magnetic resonance angiography (MRA) |
| With or without contrast enhancement? | Gadolinium\(^1\)                                                                                                                                                                                                    |
| Which planes?                        | Coronal; sagittal; axial                                                                                                                                                                                                |
| Which slice thickness?               | Standard 2-3 mm; volumetric (e.g. consecutive 1 mm)                                                                                                                                                                  |
| Which magnetic field strength?       | 1.5T, 3T, 7T                                                                                                                                                                                                           |

Key: \(^1\)T1 weighted MRI following contrast may also include (i) dynamic sequences [images obtained from multiple locations throughout the gland at multiple time points (e.g. 0, 30, 60, 90, 120 and 180 seconds) to help identify microadenomas (which exhibit delayed enhancement) or distinguish residual/recurrent tumour from postoperative change], and (ii) delayed sequences (to assess the cavernous sinuses and characterize other sella/parasellar tumours); \(^2\)Fat suppressed T1 or PD sequences may improve visualization of the posterior pituitary gland by suppressing signal from adjacent clival bone marrow.
**Table 2.** Specific indications for T2 weighted pituitary MRI – according to Bonneville(8)

<table>
<thead>
<tr>
<th>Indication</th>
<th>T2 weighted MRI findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected microprolactinoma - potential to obviate requirement for gadolinium injection</td>
<td>Hyperintense</td>
<td>(8)</td>
</tr>
<tr>
<td>Identification of silent corticotroph macroadenomas – with differentiation from non-functioning PA</td>
<td>Microcystic pattern (in &gt;50% of cases)</td>
<td>(8,48)</td>
</tr>
<tr>
<td>Investigation of GH-secreting PA: - prediction of response to first generation SSA therapy - identification of invasion of the medial wall of the cavernous sinus</td>
<td>Hypointense [commoner (&gt;50%)]: smaller tumours with less CSI, which correspond to densely granulated tumours; good response to SSA Isointense / hyperintense: larger, typically more invasive tumours; less SSA responsive</td>
<td>(8,49,50)</td>
</tr>
<tr>
<td>Diagnosis of hypophysitis</td>
<td>Hyperintense (even when overall size of gland is within normal limits)</td>
<td>(8)</td>
</tr>
<tr>
<td>Diagnosis of Rathke’s cleft cyst</td>
<td>Hypointense</td>
<td>(8)</td>
</tr>
</tbody>
</table>

**Key:** CSI, cavernous sinus invasion; PA, pituitary adenoma; SSA, somatostatin analogue therapy
### Table 3. Alternative MR sequences that have been applied in the investigation of pituitary disorders

<table>
<thead>
<tr>
<th>MRI sequence</th>
<th>Features</th>
<th>Potential application(s) in pituitary disorders</th>
<th>References</th>
</tr>
</thead>
</table>
| Diffusion weighted (DWI) | Measures the diffusion of water molecules in biological tissues; most commonly used to detect cytotoxic oedema in the context of acute cerebral ischaemia/infarction | Detection of acute pituitary apoplexy/infarction  
Distinguishing intra-/supra-sellar cystic lesions | (51)  
(52) |
| Apparent Diffusion Coefficient (ADC) | A subtype of DWI | Prediction of the consistency of PA pre-surgery:  
- some authors have reported a reduced ADC with increasing collagen content  
- others have found no relation between ADC and tumour consistency | (53–55)  
(56–58) |
| Diffusion Tensor (DTI) | An extension of DWI which analyses the directional diffusion of water molecules in biological tissue | Optic nerve tractography to inform treatment planning and predict likelihood of visual recovery following transsphenoidal surgery | (59–61) |
| Perfusion weighted (PWI) | Assesses tissue perfusion at the capillary level | Assessment of the vascularity of PA pre-surgery  
Identification of other vascular lesions (e.g. meningoia) which may be mistaken for a PA | (62)  
(63,64) |
| Magnetic Resonance Angiography (MRA) | Provides detailed images of the arterial system | Detection of intrasellar aneurysms  
Delineation of cranial nerves in their cavernous sinus segment | (65)  
(66) |
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
<th>Application</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnetic Resonance Elastography (MRE)</td>
<td>Measures the propagation of shear waves through tissue of interest to provide an estimate of stiffness.</td>
<td>Inform surgical planning by estimating whether a PA is likely to be soft (and suckable), or intermediate or firm (requiring curettage for resection)</td>
<td>(67)</td>
</tr>
<tr>
<td>Magnetic Resonance Spectroscopy (MRA)</td>
<td>Provides information on metabolic function through the measurement of different metabolites (e.g. acetylaspartate, choline, creatine)</td>
<td>Differentiation of PA from normal gland, Differential diagnosis of suprasellar lesions, Predicting response of somatotroph tumours to SSA therapy</td>
<td>(68), (69,70), (71)</td>
</tr>
<tr>
<td>Balanced steady state free precession (e.g. CISS; FIESTA)</td>
<td>Image contrast determined by T2/T1 ratio of the tissue; in practice, heavily water weighted (good contrast between CSF and other structures) but also sensitive to contrast enhancement.</td>
<td>Improved detection of adenoma in Cushing disease, Improved evaluation of cavernous sinus invasion, Prediction of adenoma consistency, Improved delineation of optic nerves and chiasm in large pituitary tumors</td>
<td>(72), (72), (73), (74)</td>
</tr>
<tr>
<td>Fluid Attenuation Inversion Recovery (FLAIR)</td>
<td>An inversion recovery sequence with a long inversion time that removes signal from the CSF which is therefore dark rather than bright as would normally be seen on T2 sequences.</td>
<td>In Cushing disease, delayed contrast washout from a corticotroph microadenoma may be detected as FLAIR hyperintensity</td>
<td>(75)</td>
</tr>
</tbody>
</table>

Key: PA, pituitary adenoma; SSA, somatostatin analogue therapy
Figure legends

**Fig. 1** Normal pituitary MRI. **a-d** Spin Echo (SE) T1 weighted coronal and sagittal sequences (pre- and post-gadolinium enhancement). **e,f** Fast Spin Echo (FSE) T2 weighted coronal and axial sequences. **Key:** Gad, gadolinium; ic-ICA, intracavernous segment of the internal carotid artery; Inf, infundibulum; OC, optic chiasm; PP, posterior pituitary gland; sc-ICA, supracavernous segment of the internal carotid artery; SpS, sphenoid sinus.

**Fig. 2** Spectrum of pituitary adenomas. **a** Left-sided microadenoma exhibiting delayed contrast enhancement (yellow arrow). **b** macroadenoma, displacing the pituitary stalk and normal remaining gland to the left (white arrow); there is only limited suprasellar extension (without compression of the optic chiasm), but clear extension in to the right cavernous sinus (yellow arrow). **c** macroadenoma with marked suprasellar extension compressing the optic chiasm (left>right) (dotted yellow arrows) and right parasellar extension (yellow arrow). **d** macroadenoma with suprasellar extension resulting in compression of the optic chiasm (dotted yellow arrows) and left parasellar extension (yellow arrow) – Knosp grade 3A (white dashed line); the remaining normal gland is seen on the right/superiorly (white arrow). **Key:** Gad, gadolinium; T1 SE, T1 weighted Spin Echo MRI.

**Fig. 3** Pituitary CT. **a,b** Macroprolactinoma with extensive right parasellar and suprasellar extension, and involvement of the skull base (yellow arrows); the position of the optic chiasm (yellow dotted arrows) and infundibulum (white arrow) are shown. **c** Intrasellar calcification (yellow arrows) in a patient with a thyrotroph adenoma.

**Fig. 4** Confirmation of suspected microprolactinoma using $^{11}C$-methionine PET. **a** Indeterminate coronal T1 weighted gadolinium enhanced SE MRI in a 22-year-old female with bilateral galactorrhoea, secondary amenorrhoea and moderate hyperprolactinaemia (PRL 3.8 $\times$ upper limit of normal), confounded by antipsychotic medication usage. **b,c** Post-gadolinium
FSPGR MRI in coronal and axial planes identifies a possible right-sided microadenoma (yellow arrows). d,e \(^{11}\text{C}\)-methionine PET/CT coregistered with FSPGR MRI confirms the site of the suspected microprolactinoma (yellow arrows). **Key:** FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; PRL, prolactin; SE, Spin Echo.

**Fig. 5** Confirmation of site of suspected residual somatotroph adenoma using \(^{11}\text{C}\)-methionine PET. a T1 weighted gadolinium enhanced SE MRI in a 50-year-old female with persistent acromegaly following transsphenoidal surgery (IGF-1 1.9 \(\times\) upper limit of normal); poorly enhancing tissue can be seen medial and inferior to the right cavernous sinus (yellow arrows), with normal enhancing tissue on the left of the sella (white arrow). b,c Post-gadolinium FSPGR MRI in coronal and axial planes confirms an area of poorly enhancing tissue on the right of the sella possibly extending in to the right cavernous sinus (yellow arrows). d,e \(^{11}\text{C}\)-methionine PET/CT coregistered with FSPGR MRI demonstrates focal tracer uptake in the right side of the sella, but without cavernous sinus extension (yellow arrows); note low level tracer uptake is also seen in the residual normal pituitary tissue (white arrow). **Key:** FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; IGF-1, insulin-like growth factor 1; SE, Spin Echo.

**Fig. 6** Identification of a left-sided corticotroph adenoma using \(^{11}\text{C}\)-methionine PET. a Indeterminate T1 weighted gadolinium enhanced SE MRI in a 32-year-old female with Cushing disease; there is minor inferior deviation of the floor of the sella on the left (yellow arrow), but no clear adenoma is seen. b bilateral inferior petrosal sinus sampling shows clear central: peripheral (>245:1 at 3 min) and right:left (>145:1 at 3 min) ACTH (ng/L) gradients following injection of 100 mcg human CRH c,d Post-gadolinium FSPGR MRI in coronal and axial planes fails to identify a definite adenoma. d,e \(^{11}\text{C}\)-methionine PET/CT coregistered with FSPGR MRI demonstrates focal tracer uptake in the left side of the gland (yellow arrows); at surgery a left-sided corticotroph adenoma was resected with resultant hypocortisolism. **Key:**
CRH, corticotrophin releasing hormone; FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; L, left; P, peripheral; R, right; SE, Spin Echo.

**Fig. 7** Identification of a right-sided thyrotroph adenoma using $^{11}$C-methionine PET. **a** Indeterminate T1 weighted gadolinium enhanced SE MRI in a 62-year-old female with a biochemically confirmed thyrotropinoma; no clear adenoma is seen. **b,c** Post-gadolinium FSPGR MRI in coronal and axial planes raises suspicion of a possible abnormality on the right side of the sella (yellow arrows), but no definite adenoma is seen. **d,e** $^{11}$C-methionine PET/CT coregistered with FSPGR MRI demonstrates intense focal tracer uptake in the right side of the gland (yellow arrows); at surgery a right-sided thyrotroph adenoma was resected with complete resolution of hyperthyroxinaemia secondary to inappropriate TSH secretion. **Key:** FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; SE, Spin Echo.

**Fig. 8** Confirmation of the site of recurrent gonadotropinoma using $^{11}$C-methionine PET. **a** T1 weighted gadolinium enhanced SE MRI in a 50-year-old male with a recurrent functioning FSH-secreting pituitary adenoma; abnormal tissue is seen in the left sella region with extension in to the sphenoid sinus (yellow arrows), but it is difficult to be sure whether this all represents recurrent disease as opposed to post-operative change; the pituitary stalk and normal gland are displaced to the right (white arrow). **b,c** Post-gadolinium FSPGR MRI in coronal and axial planes confirms the findings on SE sequences. **d,e** $^{11}$C-methionine PET/CT coregistered with FSPGR MRI demonstrates focal tracer uptake predominantly by tissue in the sphenoid sinus with only modest sella uptake (yellow arrows); the normal gland shows low level uptake of 11C-methionine (white arrow). **Key:** FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; SE, Spin Echo.

**Figure 9:** Absent $^{11}$C-methionine uptake in a pituitary cyst. **a** T1 weighted gadolinium enhanced SE MRI in a 74-year-old female with an incidentally detected right-sided pituitary cystic lesion (yellow arrow); the normal gland is seen on the left (white arrow). **b,c** Post-
gadolinium FSPGR MRI in coronal and axial planes confirms the findings on SE sequences.  

d,e  \(^{11}\)C-methionine PET/CT coregistered with FSPGR MRI demonstrates low level tracer uptake only in the normal gland (white arrows). **Key:** FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; SE, Spin Echo.
T1 SE pituitary coronal MRI

Bashari et al - Figure 2
Axial

Coronal

SE MRI

FSPGR MRI

Coregistered $^{11}$C-methionine PET/CT & FSPGR MRI

Bashari et al - Figure 5
Axial

Coronal

SE MRI

FSPGR MRI

Coregistered $^{11}$C-methionine PET/CT & FSPGR MRI

Bashari et al - Figure 9